000 04349naaaa2201069uu 4500
001 https://directory.doabooks.org/handle/20.500.12854/45509
005 20220220081904.0
020 _abooks978-3-03897-917-3
020 _a9783038979166
020 _a9783038979173
024 7 _a10.3390/books978-3-03897-917-3
_cdoi
041 0 _aEnglish
042 _adc
100 1 _aLee, Hye Suk
_4auth
700 1 _aLiu, Kwang-Hyeon
_4auth
245 1 0 _aDrug Metabolism, Pharmacokinetics and Bioanalysis
260 _bMDPI - Multidisciplinary Digital Publishing Institute
_c2019
300 _a1 electronic resource (230 p.)
506 0 _aOpen Access
_2star
_fUnrestricted online access
520 _aDrug metabolism/pharmacokinetics and drug interaction studies have been extensively carried out in order to secure the druggability and safety of new chemical entities throughout the development of new drugs. Recently, drug metabolism and transport by phase II drug metabolizing enzymes and drug transporters, respectively, as well as phase I drug metabolizing enzymes, have been studied. A combination of biochemical advances in the function and regulation of drug metabolizing enzymes and automated analytical technologies are revolutionizing drug metabolism research. There are also potential drug–drug interactions with co-administered drugs due to inhibition and/or induction of drug metabolic enzymes and drug transporters. In addition, drug interaction studies have been actively performed to develop substrate cocktails that do not interfere with each other and a simultaneous analytical method of substrate drugs and their metabolites using a tandem mass spectrometer. This Special Issue has the aim of highlighting current progress in drug metabolism/pharmacokinetics, drug interactions, and bioanalysis.
540 _aCreative Commons
_fhttps://creativecommons.org/licenses/by-nc-nd/4.0/
_2cc
_4https://creativecommons.org/licenses/by-nc-nd/4.0/
546 _aEnglish
653 _ahuman liver microsomes
653 _aalcohol addiction
653 _aUGT
653 _aultra-high-pressure liquid chromatography
653 _aadalimumab
653 _aprocainamide
653 _aLC-MS/MS
653 _aDA-9805
653 _apaeonol
653 _aLC-QTOF-MS/MS
653 _aYRA-1909
653 _achlorogenic acid
653 _aimmunoprecipitation
653 _aEurycoma longifolia
653 _aCYP
653 _acaffeic acid
653 _arat
653 _apharmaceutical excipient
653 _aKorean red ginseng extract
653 _aStauntonia hexaphylla leaf extract
653 _abioanalysis
653 _aHPLC-MS/MS
653 _aB6
653 _aeurycomanone
653 _abioavailability
653 _adrying technology
653 _aGB3
653 _adiclofenac
653 _a129-Glatm1Kul/J
653 _aaglycone
653 _acaffeic acid O-glucuronides
653 _aorganic anion transporting polypeptide
653 _aprotein precipitation
653 _ametabolic stability
653 _aFabry disease
653 _abiopharmaceuticals
653 _aimperatorin
653 _aneochlorogenic acid
653 _agastric ulcer
653 _asaikosaponin a
653 _ahair
653 _aanthraquinone
653 _aacetyl tributyl citrate
653 _apharmacokinetics
653 _abrain distribution
653 _amematine
653 _aethyl glucuronide
653 _apharmacokinetic
653 _aloxoprofen
653 _aliquid chromatography-quadrupole TOF MS
653 _aglucuronidation
653 _aesomeprazole
653 _ametformin
653 _acytochrome P450
653 _aglycoside
653 _aAUDIT score
653 _aprotein stability
653 _aefficacy
653 _aLC-HR/MS
653 _acryptochlorogenic acid
653 _aaceclofenac
653 _adrug interaction
653 _aliquid chromatography-tandem mass spectrometry
653 _aOsthenol
653 _aplasma
653 _aN-acetylprocainamide
653 _adiabetes
856 4 0 _awww.oapen.org
_uhttps://mdpi.com/books/pdfview/book/1337
_70
_zDOAB: download the publication
856 4 0 _awww.oapen.org
_uhttps://directory.doabooks.org/handle/20.500.12854/45509
_70
_zDOAB: description of the publication
999 _c75566
_d75566